fda glp-1 warning news november 2025 warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain Beyond the Headlines: FDA Warning

(By writing to us, you are agreeing to let The Atlantic use your response, which we may edit for length or clarity

If you do choose to drink, and your healthcare provider has approved it, the electrolyte strategy is straightforward

[53] Neither the patient nor the healthcare provider knew which treatment was being given until after the trials

In the same announcement, Alnylam said it would no longer work toward an expanded label for the siRNA therapeutic in cardiomyopathy of ATTR amyloidosis in the U.S

Ongoing research is exploring these issues and looking at combining GLP-1 agonists and dual agonists with other treatments for more comprehensive weight management[2][4]

For GLP-1 injections from a vial, fixed needle syringes are strongly preferred